Infectious Diseases II
1110. https://doi.org/10.1164/rccm.201408-1483oc
Timbrook TT, Morton JB, McConeghy KW, Caffrey
AR, Mylonakis E, LaPlante KL. The effect of molec-
ular rapid diagnostic testing on clinical outcomes in
bloodstream infections: a systematic review and meta-
analysis. Clin Infect Dis. 2017;64(1):15-23. https://doi.
org/10.1093/cid/ciw649
Turner SC, Seligson ND, Parag B, Shea KM, Hobbs
ALV. Evaluation of the timing of MRSA PCR nasal
screening: how long can a negative assay be used to rule
Syst Pharm. 2021;78(suppl_2):S57-S61. https://doi.
org/10.1093/ajhp/zxab109
Wagner JL, Markovich KC, Barber KE, Stover KR, Biehle
LR. Optimizing rapid diagnostics and diagnostic stew-
2021;41(8):676-685. https://doi.org/10.1002/phar.2606
Interpreting Susceptibility Reports
Kuper KM, Coyle EA, Wanger A. Antifungal suscepti-
2012;32(12):1112-1122. https://doi.org/10.1002/phar.1146
Wenzler E, Maximos M, Asempa TE, Biehle L,
Schuetz AN, Hirsch EB. Antimicrobial susceptibil-
ity testing: an updated primer for clinicians in the era
of antimicrobial resistance: insights from the Society
2023;43(4):264-278. https://doi.org/10.1002/phar.2781
Mechanisms of Antibacterial Resistance and
Treatment of Multidrug-Resistant Pathogens
Bass SN, Bauer SR, Neuner EA, Lam SW. Impact
of combination antimicrobial therapy on mortality
risk for critically ill patients with carbapenem-resis-
tant
bacteremia.
Antimicrob
Agents
Chemother.
2015;59(7):3748-3753.
https://doi.org/10.1128/
aac.00091-15
Boucher HW, Wilcox M, Talbot GH, Puttagunta S,
Das AF, Dunne MW. Once-weekly dalbavancin versus
daily conventional therapy for skin infection. N Engl J
Med. 2014;370(23):2169-2179. https://doi.org/10.1056/
nejmoa1310480
Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review
and meta-analysis of the effectiveness and safety of tige-
cycline for treatment of infectious disease. Antimicrob
Agents Chemother. 2011;55(3):1162-1172. https://doi.
org/10.1128/aac.01402-10
Centers for Disease Control and Prevention. Antimicrobial
resistance threats in the United States, 2021-2022. Centers
for Disease Control and Prevention; July 2024. https://
www.cdc.gov/antimicrobial-resistance/data-research/
threats/update-2022.html#:~:text=The%20new%20
dataA%20show,pre%2Dpandemic%20levels%20in%20
Chopra T, Marchaim D, Veltman J, et al. Impact of
cefepime therapy on mortality among patients with
bloodstream infections caused by extended-spectrum-
Ξ²-lactamase-producing Klebsiella pneumoniae and
Escherichia coli. Antimicrob Agents Chemother.
2012;56(7):3936-3942.
https://doi.org/10.1128/
aac.05419-11
Corey GR, Kabler H, Mehra P, et al. Single-dose orita-
vancin in the treatment of acute bacterial skin infections.
N Engl J Med. 2014;370(23):2180-2190. https://doi.
org/10.1056/nejmoa1310422
El-Ghali A, Kunz Coyne AJ, Caniff K, Bleick
C, Rybak MJ. Sulbactam-durlobactam: a novel
Ξ²-lactam-Ξ²-lactamase inhibitor combination targeting
carbapenem-resistant Acinetobacter baumannii infec-
org/10.1002/phar.2802
Fowler VG Jr, Boucher HW, Corey GR, et al.
Daptomycin versus standard therapy for bacteremia and
endocarditis caused by Staphylococcus aureus. N Engl
J Med. 2006;355(7):653-665. https://doi.org/10.1056/
nejmoa053783
Freire AT, Melnyk V, Kim MJ, et al. Comparison of
tigecycline with imipenem/cilastatin for the treatment
of hospital-acquired pneumonia. Diagn Microbiol
Infect Dis. 2010;68(2):140-151. https://doi.org/10.1016/j.
diagmicrobio.2010.05.012
Harris PNA, Tambyah PA, Lye DC, et al. Effect of
piperacillin-tazobactam vs meropenem on 30-day mor-
tality for patients with E coli or Klebsiella pneumoniae
bloodstream infection and ceftriaxone resistance: a ran-
https://doi.org/10.1001/jama.2018.12163
Kaye KS, Belley A, Barth P, et al. Effect of cefepime/
enmetazobactam vs piperacillin/tazobactam on clinical
cure and microbiological eradication in patients with com-
plicated urinary tract infection or acute pyelonephritis: